We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TNKASE tenecteplase 50mg powder for solution kit (Canada)
Section 19A approved medicine
TNKASE tenecteplase 50mg powder for solution kit (Canada)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN: 20605457430
Phone
1300 077 674
Approved until
Status
Current
Medicines in short supply/unavailable
METALYSE tenecteplase (rch) 50mg powder for injection vial plus prefilled syringe - ARTG 75013
Indication(s)
Indicated for the thrombolytic treatment of the acute phase of myocardial infarction.
Treatment should be initiated as soon as possible after the onset of symptoms.
Treatment can be initiated within 12 hours of symptom onset.
Images
